Medline's Stockholders Price 60 Million Shares at $35.50 Each
Medline stockholders have priced a secondary offering of 60 million shares at $35.50 per share.
Stocks · News reference
Several financial institutions, including Bernstein, BTIG, and UBS, issued updated research notes and price targets for Medline (MDLN) on November 5, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Medline stockholders have priced a secondary offering of 60 million shares at $35.50 per share.
Medline Inc. announced the pricing of a secondary offering of 60 million Class A common shares at $35.50 per share by selling stockholders affiliated with Blackstone, Carlyle Group, Hellman & Friedman, GIC Private Limited, and Abu Dhabi Investment Authority. The offering is expected to close on November 23, 2026. Medline will not receive proceeds from the sale but has agreed to repurchase $200 million of its own stock and Common Units from the selling stockholders at the same price.
Medline announced that certain existing stockholders have commenced an underwritten public offering of 60 million Class A shares, while the company simultaneously agreed to repurchase $200 million of its equity from those same stockholders.
JPMorgan analyst Lisa Gill has maintained a 'Buy' rating on Medline (MDLN) while increasing the price target from $46 to $47.
Leerink Partners has reaffirmed its 'Outperform' rating on Medline and increased its price target for the company's stock from $43 to $46.